Astria Therapeutics to Present at Upcoming Global Angioedema Forum
2024年9月27日 - 9:00PM
ビジネスワイヤ(英語)
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunologic diseases, today announced that leading HAE experts
will present two posters at the Global Angioedema Forum (GAF) in
Copenhagen, Denmark on October 4-5, 2024.
- Dr. Aleena Banerji, M.D., Associate Professor of Medicine at
Harvard Medical School and Clinical Director of the Allergy and
Immunology Unit at Massachusetts General Hospital, will present
information on ALPHA-SOLAR, a long-term open-label trial of
navenibart (STAR-0215) in people living with HAE, in an encore
presentation of a poster titled “Rationale and Design of the
ALPHA-SOLAR Clinical Trial of STAR-0215.” The poster session will
take place on Friday, October 4 at 6:00pm CEST.
- Dr. William Lumry, M.D., Clinical Professor of Internal
Medicine at the University of Texas Health Science Center at
Dallas, will present results from the Phase 1b/2 trial of
navenibart (STAR-0215) in an encore presentation of a poster titled
“ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple
Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial
Safety and Efficacy Outcomes.” The presentation will take place
during a session titled “Emerging Treatment Options” on Saturday,
October 5 at 9:30am CEST.
About Astria Therapeutics: Astria Therapeutics is a
biopharmaceutical company, and our mission is to bring
life-changing therapies to patients and families affected by
allergic and immunologic diseases. Our lead program, navenibart
(STAR-0215), is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. Our second program, STAR-0310, is a monoclonal antibody
OX40 antagonist in preclinical development for the treatment of
atopic dermatitis. Learn more about our company on our website,
www.astriatx.com, or follow us on X and Instagram @AstriaTx and on
Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240927312997/en/
Astria Contact: Investor
Relations and Media: Elizabeth Higgins
investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
過去 株価チャート
から 12 2024 まで 1 2025
Astria Therapeutics (NASDAQ:ATXS)
過去 株価チャート
から 1 2024 まで 1 2025